Trade

with

Ohr Pharmaceutical Inc
(NASDAQ: OHRP)
AdChoices
7.18
+0.07
+0.98%
After Hours :
-
-
-

Open

7.03

Previous Close

7.11

Volume (Avg)

63.12k (129.64k)

Day's Range

7.01-7.20

52Wk Range

6.01-20.00

Market Cap.

176.77M

Dividend Rate ( Yield )

-

Beta

-0.42

Shares Outstanding

24.86M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -5.65M

    • Market Cap.

    • 176.77M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.42

    • Forward P/E

    • -12.69

    • Price/Sales

    • -

    • Price/Book Value

    • 6.14

    • Price/Cash flow

    • -34.25

      • EBITDA

      • -5.56M

      • Return on Capital %

      • -36.99

      • Return on Equity %

      • -44.33

      • Return on Assets %

      • -36.99

      • Book Value/Share

      • 1.16

      • Shares Outstanding

      • 24.86M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 34.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.41

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.23

              • 2.92

              • Quick Ratio

              • 2.20

              • 2.35

              • Interest Coverage

              • -1,497.13

              • 38.02

              • Leverage Ratio

              • 1.24

              • 2.21

              • Book Value/Share

              • 1.16

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -20.53

                • 243.90

                • P/E Ratio 5-Year High

                • -56.02

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.26

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.29

                • Price/Book Value

                • 6.33

                • 8.39

                • Price/Cash Flow Ratio

                • -34.25

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -44.33

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -36.99

                        (-125.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -44.11

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -4.62M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -34.25
                      Ownership

                      Institutional Ownership

                      34.20%

                      Top 10 Institutions

                      30.06%

                      Mutual Fund Ownership

                      6.34%

                      Float

                      87.05%

                      5% / Insider Ownership

                      2.80%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • iShares Russell 2000 (AU)

                      •  

                        315,165

                      • -1.81

                      • 1.23

                      • Vanguard Total Stock Mkt Idx

                      •  

                        280,750

                      • 0.00

                      • 1.13

                      • Vanguard Extended Market Index Fund

                      •  

                        225,071

                      • 0.00

                      • 0.91

                      • iShares Russell 2000 Growth

                      •  

                        144,322

                      • -1.58

                      • 0.56

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        72,370

                      • 0.00

                      • 0.29

                      • CREF Stock

                      •  

                        65,946

                      • -2.66

                      • 0.27

                      • iShares Micro-Cap

                      •  

                        52,582

                      • 0.00

                      • 0.21

                      • AXA 2000 Managed Volatility Portfolio

                      •  

                        20,784

                      • 0.00

                      • 0.08

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Millennium Management LLC

                      •  

                        1,048,139

                      • +16.46%

                      • 4.22

                      • Vanguard Group, Inc.

                      •  

                        498,252

                      • +47.36%

                      • 2.00

                      • Goldman, Sachs & Co.

                      •  

                        214,671

                      • +58.35%

                      • 0.86

                      • State Street Corp

                      •  

                        197,785

                      • +1,605.04%

                      • 0.80

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Ohr Pharmaceutical, Inc., a Delaware corporation that is organized on August 4, 2009, as successor to, BBM Holdings, Inc., pursuant to a reincorporation merger. The Company is a biotechnology rollup company which develops its previou...moresly acquired compounds. The Company is engaged in the development of its two later stage products, OHR/AVR118 for the treatment of cancer cachexia (multi-symptom wasting disorder), and Squalamine for the treatment of the wet form of age-related macular degeneration. The Company acquired OHR/AVR118 in a secured party sale and Squalamine from the Genaera Liquidating Trust as part of the Company's previous strategy to create a rollup of undervalued biotechnology companies and assets Squalamine is a small molecule anti-angiogenic drug with a novel intracellular mechanism of ...moreaction. The drug acts against the development of aberrant neovascularization by inhibiting multiple protein growth factors of angiogenesis, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor growth factor (bFGF). On March 19, 2009, the Company acquired in a secured party sale all the patents, related intellectual property, clinical data and other assets related to AVR118 (also known now as OHR/AVR118). OHR/AVR118 is in an ongoing Phase II trial for the treatment of cachexia. OHR/AVR118 is a novel immunomodulator with a singular chemical structure that is terminally sterilized and endotoxin-free. The compound is composed of two small peptides, Peptide A, which is 31 amino acids long, and Peptide B, that is 21 amino acids long. Peptide B is unique in that the dinucleotide, diadenosine, is covalently attached to serine at position 18 through a phosphodiester bond. The Company is subject to extensive regulation by federal, state and local government authorities, including the FDA.lessless

                      Key People

                      Dr. Irach Taraporewala

                      CEO/Director/President

                      Mr. Ira A. Greenstein

                      Chairman of the Board/Director

                      Mr. Sam Backenroth

                      CFO/Vice President, Divisional

                      June Sherie Almenoff

                      Director

                      Dr. Thomas M. Riedhammer

                      Director

                      Incorporated

                      2009

                      Employees

                      2

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: